Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Suspended × lenvatinib × Clear all

Phase

Phase 2 2 Phase 2/3 1

Status

Unknown 4 Withdrawn 1 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 2 Radiotherapy 2 Radiation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 prednylidene 1 lenvatinib 1 deltacortene 1 cc-486 1 Vincristine 1 Sorafenib 1 Rituximab 1 Prednisone 1 Platinum 1 Photochemotherapy 1 Oxycodone 1 NUC-1031 1 Ketorolac 1 Ketamine 1 Ipilimumab 1 Gemcitabine 1 Folfox protocol 1 Doxorubicin 1 Cyclophosphamide 1 Cisplatin 1 CTLA-4 Antigen 1 CT-P10 1 Biopsy 1 Azacitidine 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡